IMNM
HEALTHCAREImmunome Inc
AI Insight
What's Moving IMNM Today?
No stock-specific AI insight has been generated for IMNM yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$7.96$27.65
$19.33
Fundamentals
Market Cap$2.1B
P/E Ratio—
EPS$-2.39
Dividend Yield—
Dividend / Share—
ROE-50.1%
Profit Margin—
Debt / Equity—
Trading
Volume2.2M
Avg Volume (10D)—
Shares Outstanding113.3M
IMNM News
25 articles- [Form 4] Immunome Inc. Insider Trading ActivityStock Titan·Jun 13, 2026
- Immunome Announces First Patient Dosed in Phase 1 Trial Evaluating IM-1617, a Potential First-in-Class ADC, in Patients with Advanced Solid TumorsYahoo Finance·Jun 11, 2026
- [Form 4] Immunome Inc. Insider Trading ActivityStock Titan·Jun 10, 2026
- IMNM SEC Filings - Immunome Inc 10-K, 10-Q, 8-K FormsStock Titan·Jun 10, 2026
- IMNM: Varegacestat nears launch with strong data; ADC pipeline advances with key readouts aheadTradingView·Jun 9, 2026
- 4 Biotech Stocks Investors Should Watch in 2026Yahoo Finance·Jun 5, 2026
- Immunome (IMNM) Is Down 12.7% After Phase 3 Varegacestat Data And FDA NDA Filing - Has The Bull Case Changed?Yahoo Finance·Jun 5, 2026
- Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Yahoo Finance·Jun 4, 2026
- Immunome Announces Detailed Phase 3 RINGSIDE Data for Varegacestat in Adults with Progressing Desmoid Tumors at the 2026 ASCO Annual MeetingYahoo Finance·May 30, 2026
- Barclays initiates oncology-focused biotechs with positive outlookYahoo Finance·May 28, 2026
- Immunome to Present at the Goldman Sachs 47th Annual Global Healthcare ConferenceYahoo Finance·May 27, 2026
- What Offers Immunome (IMNM) a Compelling Investment Opportunity?Yahoo Finance·May 18, 2026
- Immunome (NASDAQ: IMNM) files varegacestat NDA while Q1 loss grows on higher R&DStock Titan·May 13, 2026
- Immunome Reports First Quarter 2026 Financial Results and Provides Business UpdateYahoo Finance·May 12, 2026
- Immunome, Inc. (IMNM) Reports Submission of an NDA for Varegacestat in Desmoid TumorsYahoo Finance·May 12, 2026
- Assessing Immunome (IMNM) Valuation After Varegacestat NDA And Phase 3 Desmoid Tumor SuccessYahoo Finance·May 11, 2026
- Immunome (IMNM) moves 13.3% higher: Will this strength last?MSN·May 11, 2026
- Techne (TECH) Misses Q3 Earnings and Revenue EstimatesYahoo Finance·May 6, 2026
- Exelixis (EXEL) Tops Q1 Earnings EstimatesYahoo Finance·May 5, 2026
- CRISPR Therapeutics AG (CRSP) Reports Q1 Loss, Lags Revenue EstimatesYahoo Finance·May 4, 2026
- Immunome Announces Submission of New Drug Application to U.S. FDA for Varegacestat for the Treatment of Adults with Desmoid TumorsYahoo Finance·Apr 29, 2026
- A Look At Immunome (IMNM) Valuation As Varegacestat Nears ASCO 2026 Spotlight And FDA NDA FilingYahoo Finance·Apr 25, 2026
- Immunome Announces Oral Presentation of Phase 3 RINGSIDE Data at 2026 ASCO Annual MeetingYahoo Finance·Apr 21, 2026
- Immunome's Chief Scientist Trimmed His Stake. A Planned FDA Submission Tells You MoreThe Motley Fool·Apr 4, 2026
- Did Reduced 2025 Losses and NDA Plans Just Shift Immunome's (IMNM) Investment Narrative?Yahoo Finance·Mar 6, 2026
All 25 articles loaded
Price Data
Open$19.02
Previous Close$19.18
Day High$19.56
Day Low$19.00
52 Week High$27.65
52 Week Low$7.96
52-Week Range
$7.96$27.65
$19.33
Fundamentals
Market Cap$2.1B
P/E Ratio—
EPS$-2.39
Dividend Yield—
Dividend / Share—
ROE-50.1%
Profit Margin—
Debt / Equity—
Trading
Volume2.2M
Avg Volume (10D)—
Shares Outstanding113.3M
About Immunome Inc
Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapies for oncology and infectious diseases. The company is headquartered in Exton, Pennsylvania.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeCommon Stock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—